Acne vulgaris is a common chronic inflammatory disorder of the pilosebaceous unit that significantly affects young adults and has a negative impact on quality of life

Conventional topical therapies are effective but are often associated with adverse effects and variable patient compliance

Recent evidence suggests that the gut skin axis and intestinal microbiota play an important role in acne pathogenesis which has led to growing interest in the use of probiotics as an therapeutic option

This is a prospective randomised open label parallel group controlled clinical study conducted in the Department of Pharmacology and Dermatology at Jawaharlal Nehru Medical College Aligarh Muslim University Aligarh Uttar Pradesh India

Patients aged eighteen to thirty five years with newly diagnosed Grade one and Grade two acne vulgaris will enrolled after obtaining informed consent

A total of one hundred fifty patients will be randomly divided into two groups

Group A will receive standard topical therapy while Group B will receive standard topical therapy along with oral probiotics for twelve weeks

The primary outcome measure will be the change in acne severity assessed by the Global Acne Grading System

Secondary outcome include assessment of quality of life using the Dermatology Life Quality Index and measurement of serum testosterone levels and monitoring of adverse drug reactions

Patients will be followed up at a regular intervals during the study period

The results of this study may provide evidence for a safe and patient friendly adjunctive approach in the management of acne vulgaris